期刊
MOLECULAR AND CELLULAR ENDOCRINOLOGY
卷 358, 期 2, 页码 244-255出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2011.10.003
关键词
Endometrial carcinoma; Molecular genetics; Treatment; Target therapy; Aspirates; Mice
资金
- Spanish Ministry of Science and Innovation [SAF 2005-06771, SAF 2008-03996, SAF 2010-10635-E, SAF2011-26548]
- AECC Stable Research Groups
- CENIT Program [CENIT/01/2006]
- RTICC Program [RTICC RD06/0020/0058, RD06/0020/1034]
- Catalan Institute of Health
- Department of Universities and Research
- Catalan Government [2009SGR00487, 2005SGR00553]
- ACCIO Program [RDITSCON07-1-0001]
- Foundation La Marato de TV3 [050431]
- Fundacio Santiago Dexeus Font
- National Programme of Biotecnology [FIT-010000-2007-26]
- European Commission
- Spanish Ministry of Innovation and Science [FI07/00423]
- Spanish Ministry of Education and Science [BES-2006-14152]
- Generalitat de Catalunya [2006BPB10160]
Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15-20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometria I tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC. (C) 2011 Published by Elsevier Ireland Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据